Annual report pursuant to Section 13 and 15(d)

BUSINESS COMBINATIONS AND ASSET PURCHASES - Schedule of Pro Forma Information (Details)

v3.24.0.1
BUSINESS COMBINATIONS AND ASSET PURCHASES - Schedule of Pro Forma Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Ermont Acquisition    
Business Acquisition [Line Items]    
Revenue $ 148,948 $ 139,857
Net (loss) income $ (17,210) 6,292
Kind Therapeutics USA Inc.    
Business Acquisition [Line Items]    
Revenue   136,078
Net (loss) income   $ 15,823